Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited (AU:RAD)
:RAD
RESEARCH TOOLSreports
Total Valuation
Radiopharm Theranostics Limited has a market cap or net worth of AU$53.68M. The enterprise value is -AU$2.38M.
Market CapAU$53.68M
Enterprise Value-AU$2.38M
Share Statistics
Radiopharm Theranostics Limited has 2,333,980,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,333,980,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Radiopharm Theranostics Limited’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -67.38%.
Return on Equity (ROE)-1.71
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-67.38%
Return on Capital Employed (ROCE)-0.67
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited is -0.31. Radiopharm Theranostics Limited’s PEG ratio is -0.03.
PE Ratio-0.31
PS Ratio0.00
PB Ratio0.52
Price to Fair Value0.52
Price to FCF-0.64
Price to Operating Cash Flow-0.64
PEG Ratio-0.03
Income Statement
In the last 12 months, Radiopharm Theranostics Limited had revenue of 299.23K and earned -47.95M in profits. Earnings per share was -0.12.
Revenue299.23K
Gross Profit-21.31M
Operating Income-36.62M
Pretax Income-47.85M
Net Income-47.95M
EBITDA-45.38M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -33.42M and capital expenditures 0.00, giving a free cash flow of -33.42M billion.
Operating Cash Flow-33.42M
Free Cash Flow-33.42M
Free Cash Flow per Share-0.01
Dividends & Yields
Radiopharm Theranostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change-50.00%
50-Day Moving Average0.02
200-Day Moving Average0.03
Relative Strength Index (RSI)19.75
Average Volume (3m)4.51M
Important Dates
Radiopharm Theranostics Limited upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.
Last Earnings DateFeb 28, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date―
Financial Position
Radiopharm Theranostics Limited as a current ratio of 1.30, with Debt / Equity ratio of 0.00%
Current Ratio1.30
Quick Ratio1.30
Debt to Market Cap0.00
Net Debt to EBITDA0.41
Interest Coverage Ratio-56.96
Taxes
In the past 12 months, Radiopharm Theranostics Limited has paid 96.36K in taxes.
Income Tax96.36K
Effective Tax Rate>-0.01
Enterprise Valuation
Radiopharm Theranostics Limited EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.17.
EV to Sales-13.00
EV to EBITDA0.09
EV to Free Cash Flow0.17
EV to Operating Cash Flow0.17
Balance Sheet
Radiopharm Theranostics Limited has AU$36.44M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$36.44M billion.
Cash & Marketable SecuritiesAU$36.44M
Total DebtAU$0.00
Net Cash-AU$36.44M
Net Cash Per Share-AU$0.02
Tangible Book Value Per Share-AU$0.06
Margins
Gross margin is -1233.93%, with operating margin of -12238.44%, and net profit margin of -16024.28%.
Gross Margin-1233.93%
Operating Margin-12238.44%
Pretax Margin-15992.07%
Net Profit Margin-16024.28%
EBITDA Margin-15164.41%
EBIT Margin-16209.19%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited is AU$0.40, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$0.40
Price Target Upside1900.00% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast53.41%